Xarelto’s firm top position and Eliquis’s first 2nd in ranking
The launch of a next-generation novel oral anticoagulant(NOAC) ‘Eliquis(generic name: apixaban)’ attracted attention of the industry as becoming the top 2 prescription product for the first time in the quarter. ‘Xarelto(generic name: rivaroxaban)’ firmly kept its top position.
According to data ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
